LEADER 03940nam 2200613 a 450 001 9910818143903321 005 20251116170308.0 010 $a9781118354599 010 $a1118354591 010 $a9781118354582 010 $a1118354583 010 $a9781299241954 010 $a1299241956 010 $a9781118354575 010 $a1118354575 035 $a(OCoLC)828793860 035 $a(MiAaPQ)EBC1119446 035 $a(Au-PeEL)EBL1119446 035 $a(CaPaEBR)ebr10662566 035 $a(CaONFJC)MIL455445 035 $a(CKB)2560000000098192 035 $a(OCoLC)811003222 035 $a(FINmELB)ELB178005 035 $a(Perlego)1002463 035 $a(iGPub)WILEYB0016535 035 $a(EXLCZ)992560000000098192 100 $a20121002d2013 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 00$aFusion protein technologies for biopharmaceuticals $eapplications and challenges /$fedited by Stefan R. Schmidt 205 $a1st ed. 210 $aHoboken, N.J. $cJ. Wiley & Sons$dc2013 215 $a1 online resource (654 p.) 311 08$a9780470646274 311 08$a0470646276 320 $aIncludes bibliographical references and index. 327 $apt. 1. Introduction -- pt. 2. The triple t paradigm : time, toxin, targeting -- pt. 3. Beyond the triple t-paradigm. 330 8 $aThe state of the art in biopharmaceutical FUSION PROTEIN DESIGN Fusion proteins belong to the most lucrative biotech drugs-with EnbrelŽ being one of the best-selling biologics worldwide. EnbrelŽ represents a milestone of modern therapies just as HumulinŽ, the first therapeutic recombinant protein for human use, approved by the FDA in 1982 and OrthocloneŽ the first monoclonal antibody reaching the market in 1986. These first generation molecules were soon followed by a plethora of recombinant copies of natural human proteins, and in 1998, the first de novo designed fusion protein was launched. Fusion Protein Technologies for Biopharmaceuticals examines the state of the art in developing fusion proteins for biopharmaceuticals, shedding light on the immense potential inherent in fusion protein design and functionality. A wide pantheon of international scientists and researchers deliver a comprehensive and complete overview of therapeutic fusion proteins, combining the success stories of marketed drugs with the dynamic preclinical and clinical research into novel drugs designed for as yet unmet medical needs. The book covers the major types of fusion proteins-receptor-traps, immunotoxins, Fc-fusions and peptibodies-while also detailing the approaches for developing, delivering, and improving the stability of fusion proteins. The main body of the book contains three large sections that address issues key to this specialty: strategies for extending the plasma half life, the design of toxic proteins, and utilizing fusion proteins for ultra specific targeting. The book concludes with novel concepts in this field, including examples of highly relevant multifunctional antibodies. Detailing the innovative science, commercial realities, and brilliant potential of fusion protein therapeutics, Fusion Protein Technologies for Biopharmaceuticals is a must for pharmaceutical scientists, biochemists, medicinal chemists, molecular biologists, pharmacologists, and genetic engineers interested in determining the shape of innovation in the world of biopharmaceuticals. 606 $aRecombinant proteins 606 $aBiopharmaceutics 615 0$aRecombinant proteins. 615 0$aBiopharmaceutics. 676 $a615.7 701 $aSchmidt$b Stefan R$0174542 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910818143903321 996 $aFusion protein technologies for biopharmaceuticals$93938464 997 $aUNINA